1
|
Sicre De Fontbrune F, Barraco F, Dalle J, Forcade E, Terriou L, Berceanu A, Lebon D, Thépot S, Abraham J, Fahd M, Lioure B, Contejean A, Moluçon Chabrot C, Leblanc T, Leclerc-Teffahi S, Affinito S, Kamar D, Havet A, Bénard S, Regis P. Suivi de l’utilisation de l’Eltrombopag en vie réelle en France à partir des données de l’Observatoire National de l’Insuffisance Médullaire (RIME) : étude REVEPI. Rev Med Interne 2021. [DOI: 10.1016/j.revmed.2021.10.272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
2
|
Bénard S, Roche N, Garcia G, De Larrard A, Cancalon C, Vieu L, Mahieu A, Perez V, Demoly P. Impact en vie réelle de l’asthme sévère non contrôlé en France sur la mortalité et les consommations de soins des patients âgés de 12 ans et plus–Étude RESONANCE. Rev Epidemiol Sante Publique 2020. [DOI: 10.1016/j.respe.2020.04.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
3
|
Cottin V, Avot D, Lévy-Bachelot L, Baxter CA, Ramey DR, Catella L, Bénard S, Sitbon O, Teal S. Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database. PLoS One 2019; 14:e0214649. [PMID: 30998690 PMCID: PMC6472741 DOI: 10.1371/journal.pone.0214649] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 03/18/2019] [Indexed: 12/30/2022] Open
Abstract
Chronic thromboembolic pulmonary hypertension (CTEPH), a rare pulmonary vascular disease, is often misdiagnosed due to nonspecific symptoms. The objective of the study was to develop, refine and validate a case ascertainment algorithm to identify CTEPH patients within the French exhaustive hospital discharge database (PMSI), and to use it to estimate the annual number of hospitalized patients with CTEPH in France in 2015, as a proxy for disease prevalence. As ICD-10 coding specifically for CTEPH was not available at the time of the study, a case ascertainment algorithm was developed in close collaboration with an expert committee, using a two-step process (refinement and validation), based on matched data from PMSI and hospital medical records from 2 centres. The best-performing algorithm (specificity 95%, sensitivity 70%) consisted of ≥1 pulmonary hypertension (PH) diagnosis during 2015 and any of the following criteria over 2009-2015: (i) CTEPH interventional procedure, (ii) admission for PH and pulmonary embolism (PE), (iii) PE followed by hospitalization in competence centre then in reference centre, (iv) history of PE and right heart catheterization. Patients with conditions suggestive of pulmonary arterial hypertension were excluded. A total of 3,138 patients hospitalized for CTEPH was estimated for 2015 (47 cases/million, range 43 to 50 cases/million). Assuming that patients are hospitalized at least once a year, the present study provides an estimate of the minimal prevalence of CTEPH and confirms the heavy burden of this disease.
Collapse
Affiliation(s)
- V. Cottin
- National Reference Centre for rare pulmonary diseases, Competence centre for pulmonary arterial hypertension, Louis Pradel hospital, Claude Bernard University Lyon 1, UMR 754, Lyon, France
| | - D. Avot
- MSD France, Courbevoie, France
| | | | | | - D. R. Ramey
- Merck & Co., Inc., Kenilworth, NJ, United States of America
| | | | - S. Bénard
- stève consultants, Oullins, France
- * E-mail:
| | - O. Sitbon
- Université Paris-Sud, CHU de Bicêtre, Le Kremlin-Bicêtre, France
| | | |
Collapse
|
4
|
Barry Delongchamps N, Wagner L, Sapetti J, oinard F, Bénard S, Bensaid E, Kaegi F, Costa P. Développement d’un nouveau sphincter urinaire artificiel pour le traitement de l’incontinence urinaire d’effort chez la femme. Prog Urol 2018. [DOI: 10.1016/j.purol.2018.07.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
Cottin V, Schmidt A, Catella L, Bénard S. Prise en charge de la fibrose pulmonaire idiopathique à l’hôpital : étude rétrospective longitudinale pendant 5ans. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
6
|
Schmidt A, Bénard S. Secure System for Iv Administrations: Health Economic Impact Of A "Smart" Infusion Safety System. Value Health 2014; 17:A424. [PMID: 27201088 DOI: 10.1016/j.jval.2014.08.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- A Schmidt
- st [è] ve consultants, Oullins, France
| | - S Bénard
- st [è] ve consultants, Oullins, France
| |
Collapse
|
7
|
Schmidt A, Bénard S, Heroum C, Caumette D, Delaitre O, Le LK. Acute Ischemic Stroke (Ais) Patient Management in French Stroke Units and Impact Estimation of Thrombolysis On Care Pathways and Associated Costs. Value Health 2014; 17:A503. [PMID: 27201527 DOI: 10.1016/j.jval.2014.08.1520] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Affiliation(s)
- A Schmidt
- st [è] ve consultants, Oullins, France
| | - S Bénard
- st [è] ve consultants, Oullins, France
| | - C Heroum
- CHRU Montpellier, Montpellier, France
| | - D Caumette
- Boehringer Ingelheim France, Paris, France
| | - O Delaitre
- Boehringer Ingelheim France, Paris, France
| | - Lay K Le
- Boehringer Ingelheim France, Paris, France
| |
Collapse
|
8
|
Bénard S, Giroir-Fendler A, Vernoux P, Guilhaume N, Fiaty K. Comparing monolithic and membrane reactors in catalytic oxidation of propene and toluene in excess of oxygen. Catal Today 2010. [DOI: 10.1016/j.cattod.2010.07.019] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
9
|
Cancalon C, Schmidt A, Bénard S. La base PMSI : outil épidémiologique et économique au niveau régional. Exemple des cancers de la tête et du cou. Rev Epidemiol Sante Publique 2010. [DOI: 10.1016/j.respe.2010.02.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
10
|
Petry KU, Breugelmans JG, Bénard S, Lamure E, Littlewood KJ, Hillemanns P. Cost of screening and treatment of cervical dyskaryosis in Germany. EUR J GYNAECOL ONCOL 2008; 29:345-349. [PMID: 18714567] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
Human papillomavirus (HPV) infection is the principal cause of cervical cancer. Clinical trials with HPV vaccines have shown high efficacy against HPV-induced precancerous cervical lesions. Before implementing a vaccination programme, up-to-date data on cervical dyskaryosis, incidence and annual treatment costs are needed. We assessed resource use and costs for 12 months following diagnosis for women with abnormal Pap smears in Germany based on a sample of 138 women who had received abnormal results on Pap smears taken during March and April of 2004. Most women had a Pap IIID (57%) vs Pap III (20%) or Pap IV (23%). Women with a Pap IV consulted their gynaecologist more frequently than those with a Pap III or Pap IIID (5.6 visits vs 4.2 and 4.6 visits, respectively). Only 9% of patients underwent colposcopy plus biopsy; this may be due to the lack of histological assessment by coloposcopy and biopsy done currently in Germany. More women in the Pap IV group had a cold knife conisation, compared with those in the Pap IIID group, (84% vs 27%) hysterectomy (22% vs 4%) and laser coagulation (12.5% vs 4%). Median treatment duration was shorter for women with a Pap III than for those with Pap IIID and IV (3 vs 5 months, respectively). Overall, 28.3% of the women were hospitalised (median 5; range 1-33 days). The estimated average annual cost per patient was Euro 1,055, Euro 943 and Euro 3,174 for Pap III, IIID and IV, respectively. The cost of managing precancerous cervical lesions in Germany was shown to be high.
Collapse
Affiliation(s)
- K U Petry
- Frauenklinik im Klinikum der Stadt Wolfsburg, Wolfsburg, Germany.
| | | | | | | | | | | |
Collapse
|
11
|
Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V. [Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. ACTA ACUST UNITED AC 2007; 35:107-13. [PMID: 17270482 DOI: 10.1016/j.gyobfe.2006.12.010] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2006] [Accepted: 12/12/2006] [Indexed: 10/23/2022]
Abstract
OBJECTIVES The objectives of this study were to estimate the incidence of genital warts and treatment costs in women consulting gynaecologists in France in 2005. PATIENTS AND METHODS A prospective observational study was performed through a representative sample of gynaecologists. Investigators enrolled all patients seen with genital warts during a 2-month period. A questionnaire detailing socio-demographic characteristics, case description, patient's clinical profile, past/ current management, and treatment of genital warts was completed by the investigators. RESULTS 212 gynaecologists participated in the study. Questionnaires were completed for 263 patients including 198 (75.3%) new cases, 53 (20.2%) recurrent cases and 12 (4.5%) resistant cases. The overall incidence was estimated at 228.9/100,000 (female 15-65year old population) corresponding to 47,755 cases annually managed by gynaecologists in France. The average treatment cost was 482.70euro for society and 342.40 euro for third-party payers. The annual direct cost of genital warts management was estimated at 23,051,339euro, of which 16,351,312euro was funded by the French health care system. DISCUSSION AND CONCLUSION The costs of treating genital warts are considerable. The introduction of a quadrivalent (type 6,11,16,18) Human Papillomavirus vaccine including types responsible for 90% of genital warts could potentially substantially reduce these costs.
Collapse
Affiliation(s)
- J Monsonégo
- Institut Fournier, 174, ruedeCourcelles, 75017 Paris, France.
| | | | | | | | | | | |
Collapse
|
12
|
Bergeron C, Breugelmans JG, Bouée S, Lorans C, Bénard S, Rémy V. [Cervical cancer screening and associated treatment costs in France]. ACTA ACUST UNITED AC 2006; 34:1036-42. [PMID: 17070085 DOI: 10.1016/j.gyobfe.2006.09.005] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2006] [Accepted: 09/04/2006] [Indexed: 11/28/2022]
Abstract
OBJECTIVE Oncogenic human papillomaviruses (HPV) cause cervical cancer (CC). Screening prevents CC by detecting and removing cervical intraepithelial neoplasia (CIN) lesions that are detected through abnormal Pap smears. This study assessed the costs of CC screening, management of abnormal Pap smears, and treatment of CIN in France. PATIENTS AND METHODS Pap smears received by laboratory Pasteur-Cerba during a 7-month period were examined. Patients with abnormal Pap smears were identified and followed for 6 months after diagnosis. The management of abnormal Pap smears was documented. These data and other published studies were used to estimate the total number of pap smears, distribution of abnormal smears requiring further examinations, and number of CIN diagnosed. Economic analyses were performed to estimate total CC screening costs from the health care payer (HCP) and societal perspective. RESULTS An estimated 6,111,787 Pap smears were performed in 2004, including 222,350 abnormal (3.9%) and 63,616 follow-up smears. In total, 58,920 cervical biopsies and 52,525 HPV tests were performed after an abnormal Pap smear. The cost associated with CC screening, including management of abnormal findings, was estimated at 174.2 million euro from the HCP perspective. Total treatment cost for all CIN was estimated at 22.3 million euro (HCP perspective). DISCUSSION AND CONCLUSION Overall cost for screening, diagnosis and management of Pap smears was estimated at 335.7 million euro of which 196.5 million euro where funded by the HCP. An HPV vaccine that prevents pre-cancerous or cancerous lesions of the cervix will decrease the socio-economic burden associated with the screening of these lesions.
Collapse
Affiliation(s)
- C Bergeron
- Laboratoire Pasteur-Cerba, 95066 Cergy-Pontoise cedex 09, France.
| | | | | | | | | | | |
Collapse
|
13
|
Abstract
OBJECTIVE Infection with human Papillomavirus (HPV) is a necessary cause of cervical cancer (CC) and genital warts (GW). HPV vaccination studies have shown excellent efficacy against HPV-induced lesions. To assess the cost-effectiveness of a HPV quadrivalent (6, 11, 16 and 18) vaccine it is necessary to estimate the costs of managing current levels of HPV-related diseases. This study estimates the annual 2003 expenditures in the UK for CC screening, follow-up of abnormal findings, CC treatment and GW treatment. DESIGN AND METHODS CC screening programmes provided the annual number of screening tests, their results and use of colposcopy procedures in women with abnormal findings. Incident CC cases and hospital admissions for CC in 2003 were used to estimate CC costs. Health Protection Agency data provided the annual number of new, recurrent or persistent cases of GW treated in Genitourinary Medicine (GUM) clinics. Treatment patterns for managing GW were estimated by GUM clinicians. The annual physician visits, tests, procedures, hospital admissions and topical genital wart medications were costed to estimate the total annual expenditures for CC and GW. RESULTS There were 4.8 million screening tests and 230 303 colposcopy procedures. Estimated costs for screening, management of abnormal and inadequate findings were 138.5 million pounds sterlings. Annual management costs for incident and prevalent CC cases were 46.8 million pounds sterlings. There were an estimated 76 457 incident and 55 657 recurrent/persistent GW cases in 2003. The costs for managing these cases were approximately 22.4 million pounds sterlings. Total annual estimated costs for CC screening, management and treatment of GW were 208 million pounds sterlings and ranged from 186.9 pounds sterlings to 214 million pounds sterlings based upon sensitivity analyses. CONCLUSIONS The direct medical costs for the NHS associated with detection and management of CC, cervical dysplasia and treatment of GW in the UK are substantial. These medical costs are invaluable for future cost-effectiveness analyses of a quadrivalent HPV vaccine programme.
Collapse
Affiliation(s)
- R E Brown
- UBC Health Care Analytics Group, London, UK.
| | | | | | | |
Collapse
|
14
|
Bénard S, Yu P, Audière JP, Rivière E, Clément R, Guilhem J, Tchertanov L, Nakatani K. Structure and NLO Properties of Layered Bimetallic Oxalato-Bridged Ferromagnetic Networks Containing Stilbazolium-Shaped Chromophores. J Am Chem Soc 2000. [DOI: 10.1021/ja0002619] [Citation(s) in RCA: 180] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- S. Bénard
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - P. Yu
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - J. P. Audière
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - E. Rivière
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - R. Clément
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - J. Guilhem
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - L. Tchertanov
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| | - K. Nakatani
- Contribution from the Laboratoire de Chimie Inorganique, UMR 8613, Bt 420, Université Paris Sud, 91405 Orsay, France, the Laboratoire de Cristallochimie, Institut de Chimie des Substances Naturelles, UPR 2301, 91198 Gif-sur-Yvette, France and the P.P.S.M., Ecole Normale Supérieure de Cachan, URA 1906, avenue du Président Wilson, 94235 Cachan, France
| |
Collapse
|